AstraZeneca Results Presentation Deck
B
AstraZeneca
BUILDING A PIPELINE
OF THE FUTURE
XX
Hind
26
CEO Opening Remarks
AstraZeneca
Focused investment in pipeline of the future, rich near-term Phase III catalyst flow
NAN
Financial Results
Y
Oncology
LAURA
DESTINY-Breast06
Near-term rich catalyst flow through 2024
anselamimab
(CAEL-101)
BioPharmaceuticals
TROPION-Breast02
WAYPOINT
Rare Disease
EGFRM NSCLC
(unresectable Stg. III)
HER2-low
breast cancer (2L)
AL amyloidosis
TNBC
(locally rec. inop./met.)
CRSWNP
Confident in delivering on our ambition for industry-leading growth
CEO Closing Remarks
31 EGFRM= epidermal growth factor receptor mutation; NSCLC = non-small cell lung cancer; Stg. = Stage; HER2 = human epidermal growth factor receptor 2; 2L = 2nd-line; AL = light chain; TNBC = triple negative breast cancer; rec. =
recurrent; innop. = inoperable; met. = mestastatic; CRSwNP = chronic rhinosinusitis with nasal polyps.
H1 2024
H1 2024
H2 2024
H2 2024
H2 2024View entire presentation